Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial

Raphael Schiffmann, Ozlem Goker-Alpan, Myrl Holida, Pilar Giraldo, Laura Barisoni-Thomas, Robert B. Colvin, Charles J. Jennette, Gustavo Maegawa, Simeon A. Boyadjiev, Derlis Gonzalez, Kathy Nicholls, Ahmad Tuffaha, Mohamed G. Atta, Bonita Rup, Martha R. Charney, Alona Paz, Mali Szlaifer, Sari Alon, Einat Brill-Almon, Raul ChertkoffDerralynn Hughes

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pegunigalsidase alfa, a novel PEGylated, covalently crosslinked form of α-galactosidase A developed as enzyme replacement therapy (ERT) for Fabry disease (FD), was designed to increase plasma half-life and reduce immunogenicity, thereby enhancing efficacy compared with available products. Symptomatic adults with FD participated in this open-label, 3-month dose-ranging study, followed by a 9-month extension. Three cohorts were enrolled in a stepwise manner, each receiving increased doses of pegunigalsidase alfa: 0.2, 1.0, 2.0 mg/kg, via intravenous infusion every other week. Pharmacokinetic analysis occurred on Day 1 and Months 3, 6, and 12. Kidney biopsies at baseline and Month 6 assessed peritubular capillary globotriaosylceramide (Gb3) content. Renal function, cardiac parameters, and other clinical endpoints were assessed throughout. Treatment-emergent adverse events (AEs) and presence of immunoglobulin G (IgG) antidrug antibodies (ADAs) were assessed. Sixteen patients completed 1 year's treatment. Mean terminal plasma half-life (each cohort) ranged from 53 to 121 hours. All 11 male and 1 of 7 female patients presented with classic FD phenotype, in whom renal peritubular capillary Gb3 inclusions were reduced by 84%. Mean estimated glomerular filtration rate was 111 mL/min/1.73 m 2 at baseline, remaining stable throughout treatment. Three patients developed treatment-induced IgG ADAs; following 1 year's treatment, all became ADA-negative. Nearly all treatment-emergent AEs were mild or moderate. One patient withdrew from the study following a serious related AE. Pegunigalsidase alfa may represent an advance in ERT for FD, based on its unique pharmacokinetics and apparent low immunogenicity.

Original languageEnglish (US)
Pages (from-to)534-544
Number of pages11
JournalJournal of Inherited Metabolic Disease
Volume42
Issue number3
DOIs
StatePublished - May 1 2019

Fingerprint

Enzyme Replacement Therapy
Fabry Disease
Clinical Trials, Phase I
Kidney
Half-Life
Antibodies
Therapeutics
Pharmacokinetics
Immunoglobulin G
Galactosidases
Glomerular Filtration Rate
Intravenous Infusions
Phenotype
Biopsy

Keywords

  • antidrug antibodies
  • enzyme replacement therapy
  • Fabry disease
  • immunogenicity
  • pegunigalsidase alfa
  • pharmacokinetics

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics : A 1-year Phase 1/2 clinical trial. / Schiffmann, Raphael; Goker-Alpan, Ozlem; Holida, Myrl; Giraldo, Pilar; Barisoni-Thomas, Laura; Colvin, Robert B.; Jennette, Charles J.; Maegawa, Gustavo; Boyadjiev, Simeon A.; Gonzalez, Derlis; Nicholls, Kathy; Tuffaha, Ahmad; Atta, Mohamed G.; Rup, Bonita; Charney, Martha R.; Paz, Alona; Szlaifer, Mali; Alon, Sari; Brill-Almon, Einat; Chertkoff, Raul; Hughes, Derralynn.

In: Journal of Inherited Metabolic Disease, Vol. 42, No. 3, 01.05.2019, p. 534-544.

Research output: Contribution to journalArticle

Schiffmann, R, Goker-Alpan, O, Holida, M, Giraldo, P, Barisoni-Thomas, L, Colvin, RB, Jennette, CJ, Maegawa, G, Boyadjiev, SA, Gonzalez, D, Nicholls, K, Tuffaha, A, Atta, MG, Rup, B, Charney, MR, Paz, A, Szlaifer, M, Alon, S, Brill-Almon, E, Chertkoff, R & Hughes, D 2019, 'Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial', Journal of Inherited Metabolic Disease, vol. 42, no. 3, pp. 534-544. https://doi.org/10.1002/jimd.12080
Schiffmann, Raphael ; Goker-Alpan, Ozlem ; Holida, Myrl ; Giraldo, Pilar ; Barisoni-Thomas, Laura ; Colvin, Robert B. ; Jennette, Charles J. ; Maegawa, Gustavo ; Boyadjiev, Simeon A. ; Gonzalez, Derlis ; Nicholls, Kathy ; Tuffaha, Ahmad ; Atta, Mohamed G. ; Rup, Bonita ; Charney, Martha R. ; Paz, Alona ; Szlaifer, Mali ; Alon, Sari ; Brill-Almon, Einat ; Chertkoff, Raul ; Hughes, Derralynn. / Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics : A 1-year Phase 1/2 clinical trial. In: Journal of Inherited Metabolic Disease. 2019 ; Vol. 42, No. 3. pp. 534-544.
@article{572e265fafc24d38858bb7414be3ca97,
title = "Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial",
abstract = "Pegunigalsidase alfa, a novel PEGylated, covalently crosslinked form of α-galactosidase A developed as enzyme replacement therapy (ERT) for Fabry disease (FD), was designed to increase plasma half-life and reduce immunogenicity, thereby enhancing efficacy compared with available products. Symptomatic adults with FD participated in this open-label, 3-month dose-ranging study, followed by a 9-month extension. Three cohorts were enrolled in a stepwise manner, each receiving increased doses of pegunigalsidase alfa: 0.2, 1.0, 2.0 mg/kg, via intravenous infusion every other week. Pharmacokinetic analysis occurred on Day 1 and Months 3, 6, and 12. Kidney biopsies at baseline and Month 6 assessed peritubular capillary globotriaosylceramide (Gb3) content. Renal function, cardiac parameters, and other clinical endpoints were assessed throughout. Treatment-emergent adverse events (AEs) and presence of immunoglobulin G (IgG) antidrug antibodies (ADAs) were assessed. Sixteen patients completed 1 year's treatment. Mean terminal plasma half-life (each cohort) ranged from 53 to 121 hours. All 11 male and 1 of 7 female patients presented with classic FD phenotype, in whom renal peritubular capillary Gb3 inclusions were reduced by 84{\%}. Mean estimated glomerular filtration rate was 111 mL/min/1.73 m 2 at baseline, remaining stable throughout treatment. Three patients developed treatment-induced IgG ADAs; following 1 year's treatment, all became ADA-negative. Nearly all treatment-emergent AEs were mild or moderate. One patient withdrew from the study following a serious related AE. Pegunigalsidase alfa may represent an advance in ERT for FD, based on its unique pharmacokinetics and apparent low immunogenicity.",
keywords = "antidrug antibodies, enzyme replacement therapy, Fabry disease, immunogenicity, pegunigalsidase alfa, pharmacokinetics",
author = "Raphael Schiffmann and Ozlem Goker-Alpan and Myrl Holida and Pilar Giraldo and Laura Barisoni-Thomas and Colvin, {Robert B.} and Jennette, {Charles J.} and Gustavo Maegawa and Boyadjiev, {Simeon A.} and Derlis Gonzalez and Kathy Nicholls and Ahmad Tuffaha and Atta, {Mohamed G.} and Bonita Rup and Charney, {Martha R.} and Alona Paz and Mali Szlaifer and Sari Alon and Einat Brill-Almon and Raul Chertkoff and Derralynn Hughes",
year = "2019",
month = "5",
day = "1",
doi = "10.1002/jimd.12080",
language = "English (US)",
volume = "42",
pages = "534--544",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics

T2 - A 1-year Phase 1/2 clinical trial

AU - Schiffmann, Raphael

AU - Goker-Alpan, Ozlem

AU - Holida, Myrl

AU - Giraldo, Pilar

AU - Barisoni-Thomas, Laura

AU - Colvin, Robert B.

AU - Jennette, Charles J.

AU - Maegawa, Gustavo

AU - Boyadjiev, Simeon A.

AU - Gonzalez, Derlis

AU - Nicholls, Kathy

AU - Tuffaha, Ahmad

AU - Atta, Mohamed G.

AU - Rup, Bonita

AU - Charney, Martha R.

AU - Paz, Alona

AU - Szlaifer, Mali

AU - Alon, Sari

AU - Brill-Almon, Einat

AU - Chertkoff, Raul

AU - Hughes, Derralynn

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Pegunigalsidase alfa, a novel PEGylated, covalently crosslinked form of α-galactosidase A developed as enzyme replacement therapy (ERT) for Fabry disease (FD), was designed to increase plasma half-life and reduce immunogenicity, thereby enhancing efficacy compared with available products. Symptomatic adults with FD participated in this open-label, 3-month dose-ranging study, followed by a 9-month extension. Three cohorts were enrolled in a stepwise manner, each receiving increased doses of pegunigalsidase alfa: 0.2, 1.0, 2.0 mg/kg, via intravenous infusion every other week. Pharmacokinetic analysis occurred on Day 1 and Months 3, 6, and 12. Kidney biopsies at baseline and Month 6 assessed peritubular capillary globotriaosylceramide (Gb3) content. Renal function, cardiac parameters, and other clinical endpoints were assessed throughout. Treatment-emergent adverse events (AEs) and presence of immunoglobulin G (IgG) antidrug antibodies (ADAs) were assessed. Sixteen patients completed 1 year's treatment. Mean terminal plasma half-life (each cohort) ranged from 53 to 121 hours. All 11 male and 1 of 7 female patients presented with classic FD phenotype, in whom renal peritubular capillary Gb3 inclusions were reduced by 84%. Mean estimated glomerular filtration rate was 111 mL/min/1.73 m 2 at baseline, remaining stable throughout treatment. Three patients developed treatment-induced IgG ADAs; following 1 year's treatment, all became ADA-negative. Nearly all treatment-emergent AEs were mild or moderate. One patient withdrew from the study following a serious related AE. Pegunigalsidase alfa may represent an advance in ERT for FD, based on its unique pharmacokinetics and apparent low immunogenicity.

AB - Pegunigalsidase alfa, a novel PEGylated, covalently crosslinked form of α-galactosidase A developed as enzyme replacement therapy (ERT) for Fabry disease (FD), was designed to increase plasma half-life and reduce immunogenicity, thereby enhancing efficacy compared with available products. Symptomatic adults with FD participated in this open-label, 3-month dose-ranging study, followed by a 9-month extension. Three cohorts were enrolled in a stepwise manner, each receiving increased doses of pegunigalsidase alfa: 0.2, 1.0, 2.0 mg/kg, via intravenous infusion every other week. Pharmacokinetic analysis occurred on Day 1 and Months 3, 6, and 12. Kidney biopsies at baseline and Month 6 assessed peritubular capillary globotriaosylceramide (Gb3) content. Renal function, cardiac parameters, and other clinical endpoints were assessed throughout. Treatment-emergent adverse events (AEs) and presence of immunoglobulin G (IgG) antidrug antibodies (ADAs) were assessed. Sixteen patients completed 1 year's treatment. Mean terminal plasma half-life (each cohort) ranged from 53 to 121 hours. All 11 male and 1 of 7 female patients presented with classic FD phenotype, in whom renal peritubular capillary Gb3 inclusions were reduced by 84%. Mean estimated glomerular filtration rate was 111 mL/min/1.73 m 2 at baseline, remaining stable throughout treatment. Three patients developed treatment-induced IgG ADAs; following 1 year's treatment, all became ADA-negative. Nearly all treatment-emergent AEs were mild or moderate. One patient withdrew from the study following a serious related AE. Pegunigalsidase alfa may represent an advance in ERT for FD, based on its unique pharmacokinetics and apparent low immunogenicity.

KW - antidrug antibodies

KW - enzyme replacement therapy

KW - Fabry disease

KW - immunogenicity

KW - pegunigalsidase alfa

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85064010726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064010726&partnerID=8YFLogxK

U2 - 10.1002/jimd.12080

DO - 10.1002/jimd.12080

M3 - Article

C2 - 30834538

AN - SCOPUS:85064010726

VL - 42

SP - 534

EP - 544

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 3

ER -